Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to assess the absolute bioavailability of reslizumab following administration of a single subcutaneous (sc) dose to healthy non-Japanese participants


Clinical Trial Description

The study is designed to assess the pharmacokinetics, safety and tolerability, immunogenicity, and pharmacodynamics of reslizumab ;


Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label


Related Conditions & MeSH terms


NCT number NCT01990443
Study type Interventional
Source Teva Pharmaceutical Industries
Contact
Status Completed
Phase Phase 1
Start date June 2013
Completion date March 2014

See also
  Status Clinical Trial Phase
Completed NCT02052362 - Bioavailability of ABT-450 and ABT-267 With Ritonavir Phase 1